로딩 중…
지수 로딩 중…
한국비엔씨
256840· KOSDAQ· Health Care· Pharmaceuticals, Biotechnology & Life Sciences
₩2,350+0.00%
2026-11-02
Financials
Valuation Metrics
한국비엔씨's Market Cap is ₩1607B. At end of 2025 it was ₩3064B. Ranked #920 of 2,410 in KR market (top 38%), #434 of 1,631 on KOSDAQ (top 27%), #108 of 231 in Pharmaceuticals, Biotechnology & Life Sciences (top 47%) by Market Cap.
Investment Metrics(as of 2026-11-02)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 160.73B KRW | KR#920/2,410 Sec#108/231 |
| Revenue | 91.19B KRW | KR#1,469/2,410 Sec#90/231 |
| Net Income | -6.39B KRW | KR—/2,410 Sec—/231 |
| Total Assets | 272.49B KRW | KR#1,096/2,410 Sec#76/231 |
| Net Assets | 231.69B KRW | KR#862/2,410 Sec#58/231 |
| Employees | 266 | KR#883/2,410 Sec#73/231 |
| Value | ||
| P/B | 0.69x | KR#1,201/2,410 Sec#67/231 |
| P/S | 1.76x | KR#1,794/2,410 Sec#104/231 |
| FCF Yield | 0.09% | KR#1,210/2,410 Sec#93/231 |
| Profitability | ||
| ROE | -2.76% | KR#1,715/2,410 Sec#122/231 |
| ROA | -2.34% | KR#1,778/2,410 Sec#125/231 |
| Op. Margin | -6.15% | KR#1,893/2,410 Sec#125/231 |
| Revenue Growth | -8.21% | KR#1,877/2,410 Sec#176/231 |
| Earnings Growth | -158.08% | KR#1,214/2,410 Sec#79/231 |
| Financial Health | ||
| Debt Ratio | 17.61% | KR#310/2,410 Sec#44/231 |
| Total Debt | 25.00B KRW | KR#1,303/2,410 Sec#104/231 |
| FCF | 145.0M KRW | KR#1,212/2,410 Sec#93/231 |
| Cash | 92.75B KRW | KR#501/2,410 Sec#25/231 |
| Current Ratio | 3.51x | KR#456/2,410 Sec#68/231 |
| Dividend | ||
| Div. Yield | 2.97% | KR#705/2,410 Sec#34/231 |
| Performance | ||
| 1Y Return | -53.65% | KR#2,046/2,410 Sec#184/231 |
| 1M Return | -25.52% | KR#2,190/2,410 Sec#216/231 |
| From 52W High | -61.97% | KR#1,726/2,410 Sec#143/231 |
| 1Y MDD | -64.13% | KR#1,672/2,410 Sec#138/231 |
| Trading | ||
| Volume | 308,266 shares | KR#253/2,410 Sec#21/231 |
| Trading Value | 723.4M KRW | KR#694/2,410 Sec#70/231 |
| Foreign Own. | 4.50% | KR#950/2,410 Sec#83/231 |
| Per Share | ||
| EPS | -93 KRW | KR—/2,410 Sec—/231 |
| BPS | 3,387 KRW | KR#1,787/2,410 Sec#135/231 |
Company Info
동사는 2007년 설립되어 2019년 코스닥시장에 상장한 생체재료 기반 의료기기 전문기업임. 히알루론산과 콜라겐을 가공하여 더말필러, 보툴리눔톡신 등 미용성형용 의료기기, 창상피복재 등 수술시술용 의료기기를 개발 및 생산하며, 생명공학 관련 연구용 시약 및 키트의 바이오유통사업을 영위하고 있음. 세종시에 의약품 GMP 생산시설을 구축하여 보툴리눔톡신 국내품목허가를 획득하는 등 의료기기에서 바이오의약품으로 사업영역을 확장하고 있음. 한국비엔씨는 2016년에 설립되었으며 대구광역시 달서구에 본사를 두고 있습니다.